U.S. markets open in 6 hours 13 minutes
  • S&P Futures

    3,851.25
    +42.00 (+1.10%)
     
  • Dow Futures

    31,223.00
    +311.00 (+1.01%)
     
  • Nasdaq Futures

    13,100.50
    +189.50 (+1.47%)
     
  • Russell 2000 Futures

    2,243.10
    +43.90 (+2.00%)
     
  • Crude Oil

    62.66
    +1.16 (+1.89%)
     
  • Gold

    1,751.40
    +22.60 (+1.31%)
     
  • Silver

    27.02
    +0.58 (+2.21%)
     
  • EUR/USD

    1.2074
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3961
    +0.0039 (+0.28%)
     
  • USD/JPY

    106.6100
    +0.1080 (+0.10%)
     
  • BTC-USD

    46,400.46
    +1,885.33 (+4.24%)
     
  • CMC Crypto 200

    926.37
    -6.76 (-0.72%)
     
  • FTSE 100

    6,567.52
    +84.09 (+1.30%)
     
  • Nikkei 225

    29,663.50
    +697.49 (+2.41%)
     

Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Jan Wolfe

(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish drugmaker Forward Pharma A/S.

The U.S. Court of Appeals for the Federal Circuit said it agreed with a March 2017 ruling by the Patent Trial and Appeal Board that freed Biogen (BIIB.O) from future royalty payments to Forward.

Forward said in a statement it was disappointed with the ruling and considering its options. Biogen did not immediately respond to a request for comment.

The companies had been locked in a dispute over patents for dimethyl fumarate, the key active ingredient in Tecfidera, the leading oral MS treatment. Tecfidera had sales of about $4.2 billion in 2017.

Biogen's Tecfidera exclusivity in the United States is secured through 2028 under the ruling.

In January 2017, Biogen took out an insurance policy against a potential defeat in the patent dispute, agreeing to pay Forward $1.25 billion to license the company’s patents covering MS drugs and gain a share of Forward’s intellectual property.

The 2017 agreement would have allowed Forward to receive additional royalty payments if it had won the Federal Circuit appeal.

(Reporting by Jan Wolfe; Editing by Chizu Nomiyama and Paul Simao)